Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:45:58.048Z.
Calculation as of: 2026-10-06T22:45:58.048Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7114033928f702054061c44125c31231f02474951b0017c983a2cfe9aac3c1c
PEG RATIO
N/A
Cibus, Inc.
Market Cap
$119.84M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Cibus, Inc. (CBUS) | $119.84M | N/A |
| Seer, Inc. (SEER)vs › | $120.41M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
